Royal Marsden NHS Foundation Trust

royalmarsden.nhs.uk

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

270

Active

54

Phase 3

11

Total enrollment

10,076,176

Pipeline matrix

Showing 28 of 28 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Capecitabine3
MEDI47361
Trastuzumab1
Rucaparib1
Ramucirumab1
Palbociclib 125Mg Tab1
Fulvestrant1
Tamoxifen1
Letrozole1
Exemestane1
Anastrozole1
68Ga-PSMA1
Single agent zimberelimab1
Combination zimberelimab + domvanalimab1
Atezolizumab1
Ipatasertib 300mg1
Fulvestrant 500g1
Palbociclib 75mg-125mg1
CDK4/6 Inhibitor1
Pembrolizumab11
Avelumab3
Palbociclib1
Guadecitabine1
ASTX7271
Molecular Analysis1
DNA sequencing, RNA gene expression analysis, molecular profiling1
Molecular Analyses1
Circulating tumour DNA dynamics1

Next readouts

  • 2025-01-15
  • 2025-03-30
  • 2025-04-17
  • 2025-12-31
  • 2026-04
  • 2026-07-31
  • 2026-09
  • 2027-03-20
  • 2027-06
  • 2027-08

Top conditions

  • Breast Cancer33
  • Cancer17
  • Prostate Cancer16
  • Head and Neck Cancer14
  • Colorectal Cancer10
  • Ovarian Cancer10
  • Lung Cancer9
  • Sarcoma8

Frequently asked questions about Royal Marsden NHS Foundation Trust

How many clinical trials does Royal Marsden NHS Foundation Trust have on ClinicalTrials.gov?
Royal Marsden NHS Foundation Trust is listed as the lead sponsor on 270 clinical trials in ClinicalTrials.gov, 54 of which are currently active (recruiting, enrolling, or ongoing).
How many of Royal Marsden NHS Foundation Trust's trials are in Phase 3?
11 of Royal Marsden NHS Foundation Trust's trials are in Phase 3, spread across 28 active drug programs.
What therapeutic areas does Royal Marsden NHS Foundation Trust focus on?
Royal Marsden NHS Foundation Trust's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Cancer, Prostate Cancer, Head and Neck Cancer, Colorectal Cancer.
When are Royal Marsden NHS Foundation Trust's next clinical trial readouts?
Royal Marsden NHS Foundation Trust has 10 upcoming primary-completion readouts tracked here; the soonest is “Pembrolizumab in Muscle Invasive/Metastatic Bladder Cancer”, expected around 2025-01-15.